Peptide Dimerization as a Strategy for the Development of Antileishmanial Compounds.

Nat��lia C S Coelho, Deivys L F Portuondo, Jhonatan Lima, Angela M A Vel��squez, Val��ria Valente, Iracilda Z Carlos, Eduardo M Cilli, M��rcia A S Graminha
Author Information
  1. Nat��lia C S Coelho: Department of Clinical Analysis, School of Pharmaceutical Sciences, S��o Paulo State University (UNESP), Araraquara 14800-903, SP, Brazil. ORCID
  2. Deivys L F Portuondo: Department of Clinical Analysis, School of Pharmaceutical Sciences, S��o Paulo State University (UNESP), Araraquara 14800-903, SP, Brazil. ORCID
  3. Jhonatan Lima: Department of Clinical Analysis, School of Pharmaceutical Sciences, S��o Paulo State University (UNESP), Araraquara 14800-903, SP, Brazil. ORCID
  4. Angela M A Vel��squez: Department of Clinical Analysis, School of Pharmaceutical Sciences, S��o Paulo State University (UNESP), Araraquara 14800-903, SP, Brazil.
  5. Val��ria Valente: Department of Clinical Analysis, School of Pharmaceutical Sciences, S��o Paulo State University (UNESP), Araraquara 14800-903, SP, Brazil.
  6. Iracilda Z Carlos: Department of Clinical Analysis, School of Pharmaceutical Sciences, S��o Paulo State University (UNESP), Araraquara 14800-903, SP, Brazil. ORCID
  7. Eduardo M Cilli: Department of Biochemistry and Organic Chemistry, Institute of Chemistry, S��o Paulo State University (UNESP), Araraquara 14800-060, SP, Brazil. ORCID
  8. M��rcia A S Graminha: Department of Clinical Analysis, School of Pharmaceutical Sciences, S��o Paulo State University (UNESP), Araraquara 14800-903, SP, Brazil. ORCID

Abstract

Leishmaniasis is recognized as a serious public health problem in Brazil and around the world. The limited availability of drugs for treatment, added to the diversity of side effects and the emergence of resistant strains, shows the importance of research focused on the development of new molecules, thus contributing to treatments. Therefore, this work aimed to identify leishmanicidal compounds using a peptide dimerization strategy, as well as to understand their mechanisms of action. Herein, it was demonstrated that the dimerization of the peptide TSHa, (TSHa)K, presented higher potency and selectivity than its monomeric form when evaluated against and . Furthermore, these compounds are capable of inhibiting the parasite cysteine protease, an important target explored for the development of antileishmanial compounds, as well as to selectively interact with the parasite membranes, as demonstrated by flow cytometry, permeabilization, and fluorescence microscopy experiments. Based on this, the identified molecules are candidates for use in in vivo studies with animal models to combat leishmaniasis.

Keywords

References

  1. Molecules. 2015 Feb 06;20(2):2775-85 [PMID: 25668079]
  2. Int J Environ Res Public Health. 2020 Jul 06;17(13): [PMID: 32640562]
  3. PLoS One. 2013;8(1):e55604 [PMID: 23383240]
  4. Mar Drugs. 2016 May 19;14(5): [PMID: 27213409]
  5. Protein Pept Lett. 2019;26(2):98-107 [PMID: 30605048]
  6. Biopolymers. 2006;84(2):169-80 [PMID: 16170802]
  7. Antibiotics (Basel). 2022 Oct 16;11(10): [PMID: 36290075]
  8. FASEB J. 2008 Jun;22(6):1817-28 [PMID: 18230684]
  9. Antimicrob Agents Chemother. 2008 May;52(5):1713-20 [PMID: 18332165]
  10. J Immunol. 2003 Feb 15;170(4):1746-53 [PMID: 12574338]
  11. Antimicrob Agents Chemother. 2014 Aug;58(8):4837-47 [PMID: 24913171]
  12. J Immunol. 2004 Sep 1;173(5):3297-304 [PMID: 15322192]
  13. F1000Res. 2017 May 26;6:750 [PMID: 28649370]
  14. Curr Opin Microbiol. 2004 Aug;7(4):375-81 [PMID: 15358255]
  15. Am J Transl Res. 2019 Jul 15;11(7):3919-3931 [PMID: 31396309]
  16. Biochemistry. 2006 Dec 5;45(48):14285-97 [PMID: 17128968]
  17. Lipids. 2017 May;52(5):433-441 [PMID: 28161835]
  18. Exp Parasitol. 2004 Mar-Apr;106(3-4):158-63 [PMID: 15172223]
  19. J Nat Prod. 2017 Mar 24;80(3):756-770 [PMID: 28199101]
  20. J Control Release. 2012 Aug 10;161(3):835-42 [PMID: 22609351]
  21. Curr Drug Targets. 2012 Aug;13(9):1138-47 [PMID: 22664071]
  22. Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9258-63 [PMID: 10908670]
  23. Molecules. 2012 Oct 18;17(10):12276-86 [PMID: 23079498]
  24. PLoS One. 2017 Mar 20;12(3):e0174024 [PMID: 28319176]
  25. Med Princ Pract. 2016;25(4):301-8 [PMID: 26684017]
  26. Rev Iberoam Micol. 2015 Jul-Sep;32(3):159-63 [PMID: 25639695]
  27. Chem Phys Lipids. 2010 Jun;163(6):488-97 [PMID: 20362562]
  28. Biomed Pharmacother. 2017 Nov;95:536-547 [PMID: 28866421]
  29. Pharmacol Res. 2021 Jan;163:105276 [PMID: 33161137]
  30. Crit Rev Biotechnol. 2020 Nov;40(7):978-992 [PMID: 32781848]
  31. J Biol Chem. 2005 Jan 14;280(2):984-90 [PMID: 15513914]
  32. Front Immunol. 2012 May 15;3:99 [PMID: 22615707]
  33. Antimicrob Agents Chemother. 2017 Jul 25;61(8): [PMID: 28507113]
  34. Biochim Biophys Acta. 2007 Feb;1768(2):246-52 [PMID: 16945323]
  35. Front Bioeng Biotechnol. 2022 Dec 12;10:1051456 [PMID: 36578509]
  36. Exp Parasitol. 2020 Nov;218:107964 [PMID: 32822697]
  37. Front Cell Infect Microbiol. 2012 May 16;2:72 [PMID: 22919663]
  38. Antimicrob Agents Chemother. 2012 Jun;56(6):3004-10 [PMID: 22391524]
  39. Protein Pept Lett. 2012 Jun 1;19(6):596-603 [PMID: 22519531]
  40. Curr Trop Med Rep. 2021;8(2):121-132 [PMID: 33747716]
  41. Biochemistry. 2002 Apr 2;41(13):4425-36 [PMID: 11914090]
  42. J Nat Prod. 2012 May 25;75(5):991-5 [PMID: 22559947]
  43. Biochim Biophys Acta Gen Subj. 2017 Nov;1861(11 Pt A):2861-2871 [PMID: 28780126]
  44. Peptides. 2008 Sep;29(9):1526-33 [PMID: 18584916]
  45. Biochimie. 2013 Feb;95(2):388-99 [PMID: 23116712]
  46. Front Neurosci. 2017 Feb 14;11:73 [PMID: 28261050]
  47. Pharmaceutics. 2023 Jan 28;15(2): [PMID: 36839758]
  48. Exp Parasitol. 1983 Oct;56(2):194-206 [PMID: 6617803]
  49. PLoS One. 2021 Nov 1;16(11):e0259008 [PMID: 34723989]
  50. Rev Iberoam Micol. 2009 Dec 31;26(4):223-7 [PMID: 19836985]
  51. Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0076721 [PMID: 34633848]
  52. Amino Acids. 2014 Nov;46(11):2627-31 [PMID: 25209238]
  53. Antimicrob Agents Chemother. 2004 Aug;48(8):2980-6 [PMID: 15273109]
  54. Molecules. 2015 Aug 24;20(8):15392-433 [PMID: 26305243]
  55. Biochim Biophys Acta. 2016 Jun;1858(6):1129-38 [PMID: 26874207]
  56. J Pept Sci. 2009 May;15(5):345-52 [PMID: 19206074]
  57. Front Cell Infect Microbiol. 2019 May 10;9:153 [PMID: 31134162]
  58. J Immunol Res. 2020 Jun 18;2020:2496713 [PMID: 32656269]
  59. Biomolecules. 2022 Dec 19;12(12): [PMID: 36551331]
  60. Biochim Biophys Acta. 2008 Oct;1778(10):2308-17 [PMID: 18602889]
  61. Colloids Surf B Biointerfaces. 2018 Jul 1;167:432-440 [PMID: 29705666]
  62. Rev Soc Bras Med Trop. 2008 Sep-Oct;41(5):444-8 [PMID: 19009183]
  63. Front Cell Infect Microbiol. 2012 Jul 10;2:95 [PMID: 22919685]
  64. Pharmaceuticals (Basel). 2013 Nov 28;6(12):1543-75 [PMID: 24287494]
  65. Eur J Med Chem. 2019 Jun 1;171:116-128 [PMID: 30913526]
  66. Front Cell Infect Microbiol. 2016 Dec 27;6:194 [PMID: 28083516]
  67. J Invest Dermatol. 2003 May;120(5):810-6 [PMID: 12713586]
  68. ACS Omega. 2023 Sep 06;8(37):34008-34016 [PMID: 37744786]
  69. FEBS J. 2009 Nov;276(22):6474-82 [PMID: 19817857]
  70. PLoS Negl Trop Dis. 2018 Aug 23;12(8):e0006512 [PMID: 30138453]
  71. Res Rep Trop Med. 2019 Apr 26;10:11-18 [PMID: 31118866]
  72. Molecules. 2023 Jun 21;28(13): [PMID: 37446546]
  73. Biochemistry. 2009 Jan 20;48(2):313-27 [PMID: 19113844]
  74. Trop Med Infect Dis. 2023 Feb 25;8(3): [PMID: 36977142]
  75. Biochim Biophys Acta. 2016 Jun;1860(6):1362-72 [PMID: 27015761]
  76. Org Biomol Chem. 2015 Aug 21;13(31):8393-404 [PMID: 26130402]

Grants

  1. 22/05411-8/Funda����o de Amparo �� Pesquisa do Estado de S��o Paulo

MeSH Term

Antiprotozoal Agents
Peptides
Leishmania
Leishmania mexicana
Protein Multimerization
Animals
Leishmaniasis
Humans
Dimerization
Parasitic Sensitivity Tests

Chemicals

Antiprotozoal Agents
Peptides

Word Cloud

Created with Highcharts 10.0.0compoundsdimerizationTSHadevelopmentmoleculespeptidewelldemonstratedparasiteLeishmaniasisrecognizedseriouspublichealthproblemBrazilaroundworldlimitedavailabilitydrugstreatmentaddeddiversitysideeffectsemergenceresistantstrainsshowsimportanceresearchfocusednewthuscontributingtreatmentsThereforeworkaimedidentifyleishmanicidalusingstrategyunderstandmechanismsactionHereinKpresentedhigherpotencyselectivitymonomericformevaluatedFurthermorecapableinhibitingcysteineproteaseimportanttargetexploredantileishmanialselectivelyinteractmembranesflowcytometrypermeabilizationfluorescencemicroscopyexperimentsBasedidentifiedcandidatesusevivostudiesanimalmodelscombatleishmaniasisPeptideDimerizationStrategyDevelopmentAntileishmanialCompoundsLeishmaniaantimicrobialpeptidesmembranetemporin

Similar Articles

Cited By